| 1.62 -0.05 (-2.99%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.14 | 1-year : | 2.51 |
| Resists | First : | 1.84 | Second : | 2.14 |
| Pivot price | 1.56  |
|||
| Supports | First : | 1.54 | Second : | 1.37 |
| MAs | MA(5) : | 1.55 |
MA(20) : | 1.54 |
| MA(100) : | 1.51 | MA(250) : | 2.19  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.3 |
D(3) : | 37.7 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 4.61 | Low : | 1.13 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ IFRX ] has closed below upper band by 24.3%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.76 - 1.77 | 1.77 - 1.77 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.61 - 1.62 | 1.62 - 1.63 |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Fri, 07 Jun 2024
InflaRx's (IFRX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Wed, 05 Jun 2024
InflaRx Hosts R&D Event Highlighting the Promise of INF904 - Yahoo Finance UK
Tue, 21 May 2024
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy ... - GlobeNewswire
Wed, 08 May 2024
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
Thu, 21 Mar 2024
InflaRx N.V. Targets Immuno-Dermatology Growth - TipRanks.com - TipRanks
Tue, 19 Mar 2024
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 4.882e+007 (%) |
| Held by Institutions | 7.3 (%) |
| Shares Short | 128 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.9e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -34 % |
| Return on Assets (ttm) | 655.1 % |
| Return on Equity (ttm) | -25.3 % |
| Qtrly Rev. Growth | 99130 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -39.65 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.2 |
| Dividend | 0 |
| Forward Dividend | 71840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|